Fulvestrant administered in two different schedules: Pharmacokinetics, biological markers, and activity.
A. Felici, Paola Papaldo(Cancer Institute (WIA)), Giuseppe Naso(Policlinico Umberto I), Susanna Di Segni, Asha Tata, Francesco Angelini, Alessandra Fabi(Agostino Gemelli University Polyclinic), Francesco Cognetti(Apple (Israel)), Chiara Mandoj, Giuliana D’Auria(Ospedale di Belcolle), Laura Pizzuti, A. Antenucci, Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
|Journal of Clinical Oncology|2020|226